Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Will inter partes review speed US generic drug entry?

A new extra-judicial pathway for challenging pharmaceutical patents has intensified patent challenges and helped to clear the way for earlier generic entry.

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Leahy-Smith America Invents Act, Pub. L. No. 112–29, 125 Stat. 284 (2011).

  2. 2

    21 USC § 355(j)(2)(vii)(IV) (2017).

  3. 3

    Grabowski, H. et al. J. Med. Econ. 19, 836–844 (2016).

    Article  Google Scholar 

  4. 4

    Goldstein, R.W. & Pentcheva, D.P. 2015 Report of the Economic Survey. AIPLA (June 2015).

  5. 5

    Gleaton, A.V. et al. Finnegan (7 March, 2014).

    Google Scholar 

  6. 6

    37 CFR § 42.100(b) (2016).

  7. 7

    Phillips v. AWH Corp., 415 F.3d 1303, 1314 (Fed. Cir. 2005) (en banc).

  8. 8

    Duffy, J.F. George Washington Law Rev. 83, 28–46 (2015).

    Google Scholar 

  9. 9

    Unified Patents.

  10. 10

    Shuchman, L. Corp Counsel (9 March, 2016).

    Google Scholar 

  11. 11

    Judgment on request for adverse judgment, Lupin Limited v. Vertex Pharm. Inc., IPR2015–00405, Paper No. 28 (PTAB 3 November, 2015).

  12. 12

    Final written decision, Lupin Limited v. Vertex Pharm. Inc., No. IPR2016–00558, Paper No. 39 (PTAB 2 August, 2016).

  13. 13

    Allergan, Inc. v. Teva Pharm. USA, Inc., No. 2:15-cv-1455-WCB, 2017 WL 4619790 (E.D. Tex. 16 October, 2017) (Bryson, J.).

  14. 14

    Lewis v. Clarke, 137 S. Ct. 1285 (2017).

  15. 15

    S. 1948, 115th Cong. 1st Sess. (5 October, 2017).

  16. 16

    Oil States Energy Servs., LLC v. Greene's Energy Grp., LLC, 137 S. Ct. 2239 (2017).

Download references

Author information



Corresponding author

Correspondence to Jonathan J Darrow.

Ethics declarations

Competing interests

A.S.K. work is supported by the Laura and John Arnold Foundation, with additional support from the Harvard Program in Therapeutic Science and the Engelberg Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Darrow, J., Beall, R. & Kesselheim, A. Will inter partes review speed US generic drug entry?. Nat Biotechnol 35, 1139–1141 (2017).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing